Study of skin lupus types and how severe they are
Part of Skin clinical trials.
This study looks at adults with cutaneous lupus (skin lupus) and/or systemic lupus (a whole-body autoimmune condition) to understand how common it is and how severe the skin symptoms become. It may help researchers better describe different skin lupus forms and their impact.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older
- Have a diagnosis of cutaneous lupus (skin lupus), or
- Have a diagnosis of systemic lupus (whole-body lupus)
- Your diagnosis must meet the study’s specific medical classification rules
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if quinacrine, an oral drug, improves skin rashes caused by lupus. You may be eligible if you have a type of skin lupus called SCLE or DLE that hasn't improved with standard treatments like steroids or hydroxychloroquine.
This study creates a registry for people with lupus and their families. It helps researchers learn more about lupus and improve care. You or your child can join if you have a lupus diagnosis.
This trial tests an experimental drug called ICP-488 for people with active cutaneous lupus erythematosus (CLE), a type of lupus that affects the skin. It aims to see if the drug can reduce skin inflammation and improve symptoms.
This trial compares two drugs, lenalidomide and methotrexate, to see which works better for people with active cutaneous lupus (skin lupus) that hasn't improved with standard treatments. You would be randomly assigned to one of the two drugs and followed for several months.
This study tests an experimental medicine called VENT-03 to see if it can improve skin lupus symptoms in adults. It compares VENT-03 against a placebo (a pill with no active drug) and includes a longer-term option where everyone can get the real drug. The goal is to find a new treatment for people whose lupus affects their skin.
This study tests a new injectable drug, HC022, for people with lupus or cutaneous lupus. It aims to see if the drug is safe, tolerable, and begins to work.
Hear when a new Cutaneous Lupus Erythematosus (CLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.